Experimental Ebola trial begins in Congo as death toll tops 500
A clinical trial for experimental Ebola treatments has launched in Congo's Ituri province as the death toll from the outbreak surpasses 500. The study will test monoclonal antibodies and antivirals alongside standard supportive care.
Patients with the Bundibugyo strain of Ebola have started receiving experimental treatments in a clinical trial that aims to improve care for the rare viral disease, which has killed more than 500 people in Congo.The World Health Organization-sponsored trial will test Mapp Biopharmaceutical’s monoclonal antibody cocktail MBP134 and Gilead Sciences’s antiviral remdesivir alongside optimized supportive care in Congo’s Ituri province, where the outbreak is concentrated.Designed as an adaptive platform trial, it can continue across future Ebola outbreaks if the current epidemic ends before enough patients are enrolled to produce definitive results.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in